Evidence map›Paper›PMID 25025011›Full record

ArticleBlood research2014

Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis.

Mohsin Ilyas Malik, Mark Litzow, William Hogan, Mrinal Patnaik, Mohammad Hassan Murad, Larry J Prokop, Jeffrey L Winters, Shahrukh Hashmi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. CD11cClinical and experimental immunology · 2021
    Article
  17. Extracorporeal Photopheresis in Graft-versus-Host Disease.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohsin Ilyas MalikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA.
Mark LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA.
William HoganDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA.
Mrinal PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA.
Mohammad Hassan MuradDivision of Preventive, Occupation and Aerospace Medicine, Mayo Clinic, Rochester, USA.
Larry J ProkopLibrary and Public Services, Mayo Clinic, Rochester, USA.
Jeffrey L WintersDivision of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.
Shahrukh HashmiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe safety of extracorporeal photopheresis (ECP) in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) has been explored in multiple studies but reported response rates (RR) vary significantly across studies.

methodsWe conducted a meta-analysis to assess the efficacy of ECP for SR-cGVHD. A search of electronic databases for studies published between 1984 and 2012 was conducted. End points included RR: complete response (CR), overall response rates (ORR), and organ-specific RR. The initial search generated 312 studies, of which 18 met the selection criteria (N=595). A random effects model was used for pooled rates.

resultsPooled CR rates and ORR were 29% (confidence interval [CI], 19-42%) and 64% (CI, 65-82%), respectively. One-year overall survival was available for 4 studies only and was 49% (CI, 29-70%). The pooled RR for skin, liver, ocular, oral, lung, gastrointestinal and musculoskeletal SR-cGVHD was 74%, 68%, 60%, 72%, 48%, 53%, and 64%, respectively. There was a significant heterogeneity among studies due to differences in ECP schedules and duration. No significant differences in responses to ECP for pediatric and adult populations were found. Sensitivity analysis could not be undertaken due to a limited number of prospective studies.

conclusionECP is an effective therapy for oral, skin, and liver SR-cGVHD, with modest activity in lung and gastrointestinal SR-cGVHD.

Indexed as

Extracorporeal photopheresisGraft-versus-host diseaseMeta-analysis

Identifiers

PMID25025011
PMCPMC4090330
OpenAlexW2030530393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.